Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrx Reviewing Brand Strategy Ahead Of Fortamet Launch

Executive Summary

Andrx will launch diabetes agent Fortamet (metformin extended-release) as it is reducing emphasis on branded product development and marketing

You may also be interested in...



Andrx Fortamet Approved: Dosing Convenience Will Be Marketing Focus

Andrx will highlight the dosing convenience for Fortamet (metformin extended-release) in an effort to distinguish the antidiabetic agent from Glucophage XR and its generics

Andrx Fortamet Approved: Dosing Convenience Will Be Marketing Focus

Andrx will highlight the dosing convenience for Fortamet (metformin extended-release) in an effort to distinguish the antidiabetic agent from Glucophage XR and its generics

Andrx replaces CEO

Former Chesapeake Biological Labs CEO Thomas Rice replaces Richard Lane as Andrx' chief executive. Rice, who joined Andrx' board in April, says the change was "in no way associated with the company's finances, accounting or business conditions," but was aimed at accelerating implementation of strategic initiatives. Lane joined Andrx in June 2002 after leaving Bristol-Myers Squibb as part of a management change following disclosure of inventory problems (1"The Pink Sheet" May 27, 2002, p. 21)...

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel